company background image
EYE logo

Nova Eye Medical ASX:EYE Stock Report

Last Price

AU$0.20

Market Cap

AU$44.7m

7D

-2.4%

1Y

2.6%

Updated

01 Mar, 2024

Data

Company Financials +

EYE Stock Overview

Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally.

EYE fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Nova Eye Medical Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nova Eye Medical
Historical stock prices
Current Share PriceAU$0.20
52 Week HighAU$0.35
52 Week LowAU$0.12
Beta0.93
1 Month Change-24.53%
3 Month Change53.85%
1 Year Change2.56%
3 Year Change-42.03%
5 Year Change-65.52%
Change since IPO-66.27%

Recent News & Updates

News Flash: Analysts Just Made A Captivating Upgrade To Their Nova Eye Medical Limited (ASX:EYE) Forecasts

Jan 19
News Flash: Analysts Just Made A Captivating Upgrade To Their Nova Eye Medical Limited (ASX:EYE) Forecasts

Further Upside For Nova Eye Medical Limited (ASX:EYE) Shares Could Introduce Price Risks After 38% Bounce

Dec 27
Further Upside For Nova Eye Medical Limited (ASX:EYE) Shares Could Introduce Price Risks After 38% Bounce

Recent updates

News Flash: Analysts Just Made A Captivating Upgrade To Their Nova Eye Medical Limited (ASX:EYE) Forecasts

Jan 19
News Flash: Analysts Just Made A Captivating Upgrade To Their Nova Eye Medical Limited (ASX:EYE) Forecasts

Further Upside For Nova Eye Medical Limited (ASX:EYE) Shares Could Introduce Price Risks After 38% Bounce

Dec 27
Further Upside For Nova Eye Medical Limited (ASX:EYE) Shares Could Introduce Price Risks After 38% Bounce

We're Not Very Worried About Nova Eye Medical's (ASX:EYE) Cash Burn Rate

Sep 03
We're Not Very Worried About Nova Eye Medical's (ASX:EYE) Cash Burn Rate

Improved Revenues Required Before Nova Eye Medical Limited (ASX:EYE) Stock's 43% Jump Looks Justified

Apr 17
Improved Revenues Required Before Nova Eye Medical Limited (ASX:EYE) Stock's 43% Jump Looks Justified

Is Nova Eye Medical (ASX:EYE) In A Good Position To Invest In Growth?

Dec 16
Is Nova Eye Medical (ASX:EYE) In A Good Position To Invest In Growth?

We Think Nova Eye Medical (ASX:EYE) Needs To Drive Business Growth Carefully

Aug 27
We Think Nova Eye Medical (ASX:EYE) Needs To Drive Business Growth Carefully

Shareholder Returns

EYEAU Medical EquipmentAU Market
7D-2.4%2.1%1.3%
1Y2.6%31.4%6.6%

Return vs Industry: EYE underperformed the Australian Medical Equipment industry which returned 31.4% over the past year.

Return vs Market: EYE underperformed the Australian Market which returned 6.6% over the past year.

Price Volatility

Is EYE's price volatile compared to industry and market?
EYE volatility
EYE Average Weekly Movement20.6%
Medical Equipment Industry Average Movement10.6%
Market Average Movement8.6%
10% most volatile stocks in AU Market17.3%
10% least volatile stocks in AU Market3.4%

Stable Share Price: EYE's share price has been volatile over the past 3 months.

Volatility Over Time: EYE's weekly volatility has increased from 15% to 21% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1970n/aTom Spurlinghttps://www.nova-eye.com

Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. It offers iTrack, a surgical system for the reduction in intraocular pressure (IOP) in adult patients with open-angle glaucoma; iTrack Advance, a canaloplasty microcatheter; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020.

Nova Eye Medical Limited Fundamentals Summary

How do Nova Eye Medical's earnings and revenue compare to its market cap?
EYE fundamental statistics
Market capAU$44.71m
Earnings (TTM)-AU$14.31m
Revenue (TTM)AU$18.77m

2.3x

P/S Ratio

-3.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EYE income statement (TTM)
RevenueAU$18.77m
Cost of RevenueAU$1.83m
Gross ProfitAU$16.94m
Other ExpensesAU$31.25m
Earnings-AU$14.31m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.067
Gross Margin90.24%
Net Profit Margin-76.24%
Debt/Equity Ratio0%

How did EYE perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.